Nwam LLC Purchases Shares of 8,047 AstraZeneca PLC (NASDAQ:AZN)

Nwam LLC acquired a new position in shares of AstraZeneca PLC (NASDAQ:AZN) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 8,047 shares of the company’s stock, valued at approximately $627,000.

Several other institutional investors have also made changes to their positions in AZN. Meridian Wealth Management LLC bought a new position in shares of AstraZeneca during the 3rd quarter worth approximately $1,005,000. Biltmore Family Office LLC bought a new position in shares of AstraZeneca during the third quarter valued at $230,000. Charles Schwab Investment Management Inc. boosted its stake in shares of AstraZeneca by 0.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,784,235 shares of the company’s stock valued at $139,010,000 after purchasing an additional 8,830 shares in the last quarter. Smithfield Trust Co grew its holdings in shares of AstraZeneca by 11.4% in the 3rd quarter. Smithfield Trust Co now owns 4,619 shares of the company’s stock worth $358,000 after purchasing an additional 471 shares during the last quarter. Finally, Blackhawk Capital Partners LLC. acquired a new stake in shares of AstraZeneca during the 3rd quarter worth about $245,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AZN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Trading Up 2.1 %

AZN stock opened at $65.63 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68. The company has a market cap of $203.49 billion, a P/E ratio of 31.40, a PEG ratio of 1.20 and a beta of 0.47. The business has a fifty day moving average of $73.44 and a 200-day moving average of $77.80.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the previous year, the business posted $0.87 EPS. As a group, equities research analysts expect that AstraZeneca PLC will post 4.1 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.